Investor Overview

Corporate Profile

vTv Therapeutics is a clinical stage biotechnology company committed to improving the lives of diabetes patients.

vTv has a pipeline of clinical drug candidates developed using our innovative technology and led by our TTP399 program for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, renal disease, primary mitochondrial myopathy, and pancreatic cancer.

More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022 , and provided an update on the progress of its clinical programs. Recent Achievements and Outlook Corporate Strategic Focus.
View HTML
Toggle Summary vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
HIGH POINT, N.C. , March 29, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021 , and provided an update on the progress of its clinical programs. "I am dedicated to the long-term growth and development
View HTML
Toggle Summary vTv Therapeutics Announces CEO Transition
HIGH POINT, N.C. , March 3, 2022 /PRNewswire/ --  vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, today announced that the Company has appointed Rich Nelson as Acting Chief Executive
View HTML
Toggle Summary vTv Therapeutics Shares Updated Corporate Presentation
HIGH POINT, N.C. , Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral
View HTML
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.